Background: While cardiac rehabilitation in patients with ischaemic heart disease and heart failure is considered costeffective, this evidence may not be transferable to heart valve surgery patients. The aim of this study was to investigate the cost-effectiveness of cardiac rehabilitation following heart valve surgery. Design: We conducted a cost-utility analysis based on a randomised controlled trial of 147 patients who had undergone heart valve surgery and were followed for 6 months. Methods: Patients were randomised to cardiac rehabilitation consisting of 12 weeks of physical exercise training and monthly psycho-educational consultations or to usual care. Costs were measured from a societal perspective and qualityadjusted life years were based on the EuroQol five-dimensional questionnaire (EQ-5D). Estimates were presented as means and 95% confidence intervals (CIs) based on bootstrapping. Costs and effect differences were presented in a cost-effectiveness plane and were transformed into net benefit and presented in cost-effectiveness acceptability curves. Results: No statistically significant differences were found in total societal costs (-1609 Euros; 95% CI: -6162 to 2942 Euros) or in quality-adjusted life years (-0.000; 95% CI -0.021 to 0.020) between groups. However, approximately 70% of the cost and effect differences were located below the x-axis in the cost-effectiveness plane, and the cost-effectiveness acceptability curves showed that the probability for cost-effectiveness of cardiac rehabilitation compared to usual care is at minimum 75%, driven by a tendency towards costs savings. Conclusions: Cardiac rehabilitation after heart valve surgery may not have improved health-related quality of life in this study, but is likely to be cost-effective for society, outweighing the extra costs of cardiac rehabilitation.
Introduction
Exercise-based cardiac rehabilitation (CR) for patients with ischaemic heart disease (IHD) and heart failure has been investigated, and is considered cost-effective.
1,2 These findings may not be transferable to other cardiac populations, including patients undergoing heart valve surgery, particularly those without concomitant IHD. There is limited knowledge on the health care needs following heart valve surgery 3 and no studies have investigated the cost-effectiveness of CR for these patients.
Investigating the cost-effectiveness of CR for patients following heart valve surgery is important for several reasons. First, the incidence rates of heart valve diseases and the numbers of heart valve procedures are increasing. Secondly, even though the prevalence of heart valve diseases is low compared to, for example, patients with IHD, their investigation and treatment costs to the health care system are significant. 4 Thirdly, health care use and therefore costs are substantial following heart valve surgery, with high readmission rates of up to 56% described within the first year post-surgery. 5, 6 Finally, while health-related quality of life (HRQL) typically improves overall after heart valve surgery, 7 HRQL is lower compared to matched general populations at up to 12 months after surgery, 5 indicating the potential of CR for these patients.
A recent Danish nationwide survey of patients undergoing heart valve surgery demonstrated no significant differences in total costs or other categories of primary care visits, inpatient hospital admissions, prescription medication or sick leave costs, and concluded that CR, when compared to non-participation, can be considered cost-neutral and may even offset more expensive outpatient visits. 8 However, the study contained no information on HRQL or other patientreported outcomes, which are crucial to informing health policy planning regarding the attractiveness of CR as a routine practice. Within the field of CR, cost-utility analyses are particularly warranted. These are similar to cost-effectiveness analyses, but with quality-adjusted life years (QALYs) as the outcome, simultaneously capturing changes in both mortality and HRQL. 2 The aim of the current study was to investigate the cost-utility of CR in patients following heart valve surgery who were randomised to CR versus usual care.
Methods

Study design
We conducted a cost-utility analysis carried out alongside a randomised controlled trial, CopenHeart VR , 9 of 147 patients undergoing heart valve surgery who were randomised to CR (n ¼ 72) or usual care (n ¼ 75). The power calculation was based on the primary outcome of the trial: physical capacity measured by VO 2 peak. The original recruitment target was 210. However, due to difficulties in recruitment, a time point for terminating inclusion was established, and a sample size of 147 patients was reached. The power was recalculated before the data analysis of the accrued sample. 10 Full details of the trial protocol and ethical approvals, 9 as well as the clinical outcomes of the CopenHeart VR trial, 10 are available. Briefly, the main finding of the clinical trial was that CR significantly improves VO 2 peak at 4 months. 10 According to current guidelines, all patients received a physical examination and biochemical and echocardiographic assessment from the referral hospital following surgery. 11 Costs and outcomes were evaluated from the date of discharge and until 6 months post-surgery, which was considered an adequate length of follow-up, since costs are mainly incurred within the first months post-surgery, 8 and mortality rates are considered low following surgery. 4, 5 Population, setting and location Trial participants were recruited at a large Danish University Hospital between February 2012 and May 2014. Inclusion criteria were undergoing elective rightor left-sided conventional heart valve surgery, age 18 years or older and able to speak and understand Danish. Exclusion criteria were IHD, participation in other CR programmes by the time of recruitment, diseases complicated by physical activity, participation in competitive sports and pregnancy and/or breastfeeding. 9 
Study perspective
The study adopted a societal perspective with total societal costs that included intervention costs, follow-up costs in the health care sector (primary and secondary care and prescription medication) and broader costs to society (productivity loss due to long-term sick leave and patient-borne costs associated with CR participation).
Cardiac rehabilitation
Trial participants randomised to CR participated in a 12-week physical exercise training programme with three weekly sessions consisting of graduated cardiovascular training and strength exercises. One exercise protocol was applied to all participants, but individualised where necessary. The programme was initiated at hospital and continued either at a hospital or municipality-certified locations (69%) or as home-based training with an exercise cycle ergometer or as self-training in a fitness centre (31%), and some participants chose to combine the modes of delivery. Also, trial participants randomised to CR participated in a psycho-educational intervention consisting of five monthly nurse consultations aimed at improving disease coping by applying a patient-centred approach, which was initiated within the first month after surgery. 10 
Usual care
Participants randomised to usual care gave written consent agreeing not to participate in structured hospital or municipality service CR. All CR participation outside of the trial protocol was monitored using a 6-month follow-up self-reported questionnaire and subsequent telephone-based contacts. 9 
Costing
The costs of CR and patient-borne costs were estimated from micro-costing, 12 and all other costs were estimated from administrative nationwide health care service registers. All costs were inflated to 2014 Euros using the general consumer price index and a currency conversion rate of 745 DKK ¼ 100 Euros. No discounting was undertaken due to the time horizon.
Cardiac rehabilitation costs. The costs of CR included costs associated with physical exercise training, nurse consultations and equipment used for physical exercise training. Equipment included pulse watches provided to participants in the CR group. CR participants electing either a fitness centre or a cycle ergometer for homebased training were required to incur those costs.
Resource use associated with physiotherapist and nurse consultations was estimated based on health care professionals' time registrations and valued using average wage tariffs, which were loaded with a factor of 1.6 to account for non-productive time. Some participants in the CR group received only physical exercise training or nurse consultations, in which case costs associated with non-participation for either of the elements were valued at 0 Euros. Equipment costs for physical exercise training were estimated using market prices. Overhead costs of 3.1% were allocated.
For participants in the usual care group who, despite written consent, participated in CR outside of the trial protocol, costs were estimated using national tariffs. Based on observations of a national cohort of similar patients undergoing heart valve surgery, it was assumed that those trial participants completed 8.6 physical training sessions. 8 Primary health care costs. Resource use in primary health care was obtained from the Danish National Health Service Register 13 and valued using tariffs of the national agreements between the Danish National Health Service and professional associations of medical specialists. We categorised service providers into general practitioners (codes 80-84, 89), medical specialists (codes 1-21, 23, 24), physiotherapists (codes 51, 62) and psychologists (code 63).
Secondary health care costs. Resource use of secondary health care (in-and out-patient hospital-based services) was derived from the Danish National Patient Registry 14 and valued using tariffs of the case-mix system of Diagnosis-Related Grouping (DRG) for inpatient admissions and the Danish Ambulatory Grouping System (DAGS) for outpatient contacts. Inpatient admissions were categorised as acute or non-acute cardiovascular versus other admissions, and outpatient contacts were categorised as cardiovascular versus other contacts.
Prescription medication costs. Use of prescription medication outside hospitals was extracted from the Danish National Prescription Register. 15 Medication was categorised based on Anatomical Therapeutic Chemical classification codes into: antithrombotic agents including anti-coagulant treatment (B01A); anti-arrhythmic medication (C01BD01, C01BD07); analgesics (M02, N02); psycholeptics (N05A); other cardiovascular medication; and other medication. Medication use was quantified using the defined daily dose 16 and valued by the retail price.
Sick leave costs. Sick leave weeks among trial participants who were part of the labour force at baseline were acquired from the national Labour Market Authority's database (DREAM) and valued using national age-and gender-matched gross wages. Only sick leave lasting for more than 2 weeks is registered in the DREAM database. 17 Patient-borne costs. Time and costs spent on CR participation were obtained from patient diaries and self-reported questionnaires. In case of missing data, estimates for these sessions were based on average figures from other sessions within the same participants. The duration of sessions typically ranged from 45 to 60 minutes.
Time spent on CR and transportation was valued using the opportunity cost method and based on national average gender-and age-matched net salaries for those who were part of the labour force at baseline. The value of time for those outside the labour force was set to zero in the base case. Costs associated with vehicular transportation to and from CR facilities were estimated by assuming that 1 km of transportation took 1 minute and was valued by the official Danish mileage tariff of 0.28 Euros per kilometre: foot or bicycle transportation costs were valued at 0 Euros.
Quality-adjusted life years
The five level version of the EQ-5D (EQ-5D-5L) 18 was used to measure HRQL at baseline and after 6 months of follow-up. Aggregation from the five-level to threelevel item responses was conducted based on an established methodology because Danish preference weights are not yet available for the five-level version. 19 Danish preference weights were used to calculate utility scores and QALYs. 20 
Handling of missing data
The EQ-5D-5L instrument responses contained missing data at baseline and 6 months of follow-up distributed unequally between the groups (participants in the CR group: n ¼ 1 at baseline and n ¼ 7 at 6 months of followup; in the usual care group, the corresponding figures were 11 and 17).
Full QALY calculation was performed for a total of 119 participants (81%), with 118 participants having no missing data at either point in time and one participant in the usual care group dying 3 days after randomisation. Missing data were assumed to be missing at random and handled by inverse probability weighting (IPW) of complete response cases. 21 Logistic regression was used to calculate the probability weights and included variables of the randomisation group and hospital admissions in the base case, as these variables significantly explained non-response.
Cost-utility analysis
Resource use, costs and outcomes were presented as means and between-group differences with 95% confidence intervals (CIs) based on non-parametric bootstrapping with 5000 replicates. 22 For differences in resource use and costs, adjustment was made for sick leave before randomisation because the randomisation procedure was not successful in allocating individuals randomly with respect to this particular characteristic. 23 The uncertainties in the cost and QALY estimates were presented in a scatter plot of bootstrapped cost and effect differences. These were transformed into net benefit to generate the cost-effectiveness acceptability curve, which illustrates the probability of CR being cost-effective over usual care for a range of hypothetical threshold values of willingness to pay for a QALY. 24 The cost-effectiveness acceptability curve approach was also used for illustrating the results of sensitivity analysis, including alternative scenarios of the valuation of patient time, an alternative IPW model specification including variables considered likely to predict nonresponse, restriction of the analysis to complete cases alive at 6 months of follow-up and per-protocol analysis.
Results
Baseline characteristics
Baseline characteristics in the 147 randomised trial participants showed a minor gender imbalance that was considered to occur by chance. However, there was a pre-randomisation difference between groups with regards to sick leave (Table 1) , for which the analyses were adjusted. A total of 61/72 (85%) in the CR group 
Costs
Resource use and costs of care are presented in Tables 2  and 3 , respectively. The total costs in the CR group were estimated to be 882 Euros per patient. In the usual care group, 13/75 participants received CR outside of the trial protocol and the costs for these participants were estimated at 132 Euros per patient. Statistically significantly higher CR costs and patientborne costs were observed in the CR group compared to the usual care group. No statistically significant differences were observed for health care use, sick leave or associated costs, except for a statistically significant difference in other acute hospital admission costs, which was due to a higher number of hospital admissions in the usual care group and to extreme cost observations. The overall societal costs per patient were estimated at 14,185 Euros in the CR group and at 17,448 Euros in the usual care group, leading to a non-significant difference of -1609 Euros (95% CI: -6162 to 2942) in favour of the CR group, after adjusting for pre-sick leave costs. Values are mean costs and mean differences (95% CI).
a Adjustments made for pre-sick leave costs before randomisation. CI: confidence interval; CR: cardiac rehabilitation,
Outcomes
No statistically significant differences in EQ-5D HRQL scores or QALYs were found between the groups based on either complete response analysis or on the weighted complete response analysis (Table 4) .
Cost-utility
The cost and QALY differences were located in all four quadrants of the scatter plot, which indicates substantial uncertainty about the cost-effectiveness of CR ( Figure 1a) . As approximately 70% of the cost and QALY differences were located below the x-axis, CR has a high probability of being cost-saving. However, cost and QALY differences were also spread almost equally to the left and right of the y-axis, suggesting that CR holds only a 50% probability of providing a better outcome. The cost-effectiveness acceptability curves for the base case analysis and for the sensitivity analysis including alternative scenarios showed a similar trend, namely that the probability for cost-effectiveness is at minimum 75% and does not increase for increasing values of willingness to pay due to the lack of a QALY benefit of CR (Figure 1b) . The probability for Based on responses at both baseline and at 6 months. b Based on inverse probability weights accounting for variables significantly explaining non-response (randomisation group and number of hospital admissions during follow-up). CI: confidence interval; CR: cardiac rehabilitation; EQ-5D: EuroQoL 5 Dimensions; QALY: quality-adjusted life year.
cost-effectiveness is thus driven largely by the observed tendency for societal cost savings. The most significant impact of the sensitivity analysis was demonstrated by the per-protocol analysis, in which the maximum probability for cost-effectiveness reached 90%.
Discussion
Study findings
We investigated the cost-utility of a CR programme for patients following heart valve surgery using data from a randomised trial, CopenHeart VR , 10 which is the largest such trial to date, with CR programme costs estimated at 882 Euros and patient-borne CR costs estimated at 309 Euros. No statistically significant differences were found between the groups for costs or QALYs, but due to a tendency for societal cost savings when CR is provided, the probability for cost-effectiveness is in favour of CR.
Comparison with other studies
This study is the first investigation of the cost-utility of CR among patients undergoing heart valve surgery. Previous CR studies suggest that the cost-utility of hospital-based CR versus usual care among patients with myocardial infarction is between $650/QALY 25 and $9200/QALY. 26 In addition, the mode of delivery has been examined for patients with IHD. Costs per QALY of between $0 and $11,400 have been reported for hospital-based versus home-based CR.
2 Costconsequence analyses support both hospital and home-based CR as equally cost-effective or costsaving interventions compared to usual care in coronary and heart failure patients. 2 In this study we cannot tell whether the modalities involved may have influenced the results of the analysis.
A systematic review of the cost-effectiveness studies of CR demonstrates a variety of study perspectives, CR interventions, comparators and lengths of follow-up, making comparison across studies difficult, 2 but importantly, unlike these studies, we did not find an effect of CR on HRQL. This could have several explanations. The timing and the intensity of CR and, in particular, the psycho-educational intervention may not be adequate for patients following heart valve surgery. Overall, CR was initiated 4 weeks after surgery, which we believe may have been too late for this population in which high levels of complications and readmissions frequently occur within the first months following surgery. 5 Future studies should evaluate CR interventions with some components having already been initiated post-discharge. The level of adherence to CR was relatively high in our study compared to previously reported levels in a real-life setting. 27 The length of follow-up in our study was shorter than some of the studies conducted among patients with IHD. 2 In regard to costs, a time horizon of 6 months from surgery was considered adequate since costs were mainly incurred within the first months after discharge in our population, as was demonstrated in a non-randomised but nationwide cost analysis of consecutive patients undergoing heart valve surgery. 8 Strengths, limitations and external validity of the study
The strengths of this study include randomisation to the CR intervention and complete information on costs with no losses to follow-up based on multiple registers. Further, none of the alternative scenarios included in the sensitivity analysis altered the overall findings.
There are several limitations to the study. Sample size calculations for the clinical trial were based on the primary outcome (improvement in VO 2 peak), 10 the economic evaluation was conducted alongside the clinical trial and a large proportion of patients declined to participate in the trial. The numbers of patients were unequal in the groups due to the early termination of the trial. 10 However, the drop-out rates in the two groups were also uneven, and therefore we do not believe that the difference in the number of patients in the groups at baseline significantly impacted the results.
In both groups, baseline EQ-5D scores were high, indicating that this population may not be representative of heart valve surgery patients broadly. Future studies should investigate the cost and effects of CR in specific groups of patients undergoing heart valve surgery that may benefit from CR differently, such as elderly patients with aortic stenosis or patients with different levels of functional capacity, or such studies should include a larger sample of patients in order to allow for subgroup analyses. In addition, studies with longer follow-up periods are recommended.
The EQ-5D instrument may not be suitable for outcome assessment in this population, which, to some extent, experiences spontaneous recovery, but may also experience problems at 6 months that are not captured by generic HRQL instruments. Further, a considerable minority of the usual care group (17.3%) participated in CR. However, the per-protocol analysis did not alter the overall finding of the study. Missing outcome data were handled through analyses of complete cases and by IPW of these and were tested in alternative scenario models. Finally, the study was conducted in a Danish context, which limits generalisation to other countries.
Conclusion
Even though CR following heart valve surgery in these Danish patients did not improve short-term HRQL, it does hold a high probability of being cost-effective for society due to fewer hospital inpatient admissions and less sick leave, which outweigh the extra costs of CR.
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